Nevertheless, as the disease progresses, due to a lack of neuroprotective drugs, there remains a great unmet need for effective neuroprotective or disease-modifying therapies 11
10.1016/j.intimp.2019.105950 94 ZhongN
Patient-Friendly Timeline Retatrutide, CagriSema, and orforglipron are currently in Phase 3 testing
It has been demonstrated that ebselen possesses otoprotective activity and alleviated NIHL in rat via preventing the loss of outer HCs and reduces the acute swelling of the stria vascularis ( gpx1 knockout ( gpx1 / ) mice to investigate the role of GPX1 in SGNs treated with peroxynitrite
A few commenters urged CMS to provide details on how the determination of an exception versus an extension will be made to ensure transparency
L., Wilkinson, D., Smith, K., Greenhaff, P